Ars Pharmaceuticals targets cash flow breakeven by year-end 2027 as neffy U.S. share surpasses 5%
Seeking Alpha ·
ARS Pharmaceuticals Q3 2026: neffy sales and market share rose as costs fell, supporting 2027 breakeven goals.
Ars Pharmaceuticals targets cash flow breakeven by year-end 2027 as neffy U.S. share surpasses 5%
ARS Pharmaceuticals Q3 2026: neffy sales and market share rose as costs fell, supporting 2027 breakeven goals.
1 sources · 1 articles · updated 2026-11-06 13:25 UTC · business